0001104659-21-023961.txt : 20210216
0001104659-21-023961.hdr.sgml : 20210216
20210216161007
ACCESSION NUMBER: 0001104659-21-023961
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210211
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dorval Allison
CENTRAL INDEX KEY: 0001625110
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37625
FILM NUMBER: 21638368
MAIL ADDRESS:
STREET 1: C/O INSULET CORPORATION
STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Voyager Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640266
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-5340
MAIL ADDRESS:
STREET 1: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
tm216891-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-02-11
0
0001640266
Voyager Therapeutics, Inc.
VYGR
0001625110
Dorval Allison
C/O VOYAGER THERAPEUTICS, INC.,
75 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Financial Officer
Common Stock
2021-02-11
4
S
0
3186
7.55
D
45894
D
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ Allison Dorval
2021-02-16